Crescent Biopharma (CBIO) Total Current Liabilities (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Total Current Liabilities data on file, last reported at $14.2 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $14.2 million, up 442.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.2 million (up 442.35% YoY), and the FY2025 annual result was $36.1 million, up 275.2% from the prior year.
• Total Current Liabilities retreated to $14.2 million in Q1 2026 per CBIO's latest filing, from $36.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $36.1 million in Q4 2025 and troughed at $2.6 million in Q1 2025.
• A 5-year average of $10.5 million and a median of $7.7 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities tumbled 50.57% in 2025, then surged 442.35% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $8.9 million in 2022, then fell by 23.03% to $6.8 million in 2023, then surged by 40.65% to $9.6 million in 2024, then soared by 275.2% to $36.1 million in 2025, then plunged by 60.65% to $14.2 million in 2026.
• Business Quant data shows CBIO's Total Current Liabilities at $14.2 million in Q1 2026, $36.1 million in Q4 2025, and $20.3 million in Q3 2025.